Clinical Utility of Rush Venom Immunotherapy: Current Status

References

• Worm M, Moneret‐Vautrin A, Scherer K, et al. First European data from the network of severe allergic reactions (NORA). Allergy. 2014;69(10):1397–1404. doi:10.1111/all.1247524989080
   PubMed Web of Science ®Google Scholar
• Grabenhenrich LB, Dölle S, Moneret-Vautrin A, et al. Anaphylaxis in children and adolescents: the European Anaphylaxis Registry. J Allergy Clin Immunol. 2016;137(4):1128–1137. e1121. doi:10.1016/j.jaci.2015.11.01526806049
   PubMed Web of Science ®Google Scholar
• Antonicelli L, Bilò MB, Bonifazi F. Epidemiology of Hymenoptera allergy. Curr Opin Allergy Clin Immunol. 2002;2(4):341–346. doi:10.1097/00130832-200208000-0000812130949
   PubMed Web of Science ®Google Scholar
• Clifford D, Ni Chaoimh C, Stanley E, O’B Hourihane J. A longitudinal study of hymenoptera stings in preschool children. Pediatr Allergy Immunol. 2019;30(1):93–98. doi:10.1111/pai.2019.30.issue-130298641
   PubMed Web of Science ®Google Scholar
• Jakob T, Rafei-Shamsabadi D, Spillner E, Müller S. Diagnostics in Hymenoptera venom allergy: current concepts and developments with special focus on molecular allergy diagnostics. Allergo J Int. 2017;26(3):93–105. doi:10.1007/s40629-017-0014-228503403
   PubMedGoogle Scholar
• Bilo M, Bonifazi F. The natural history and epidemiology of insect venom allergy: clinical implications. Clin Exp Allergy. 2009;39(10):1467–1476. doi:10.1111/cea.2009.39.issue-1019622088
   PubMed Web of Science ®Google Scholar
• Novembre E, Cianferoni A, Bernardini R, et al. Epidemiology of insect venom sensitivity in children and its correlation to clinical and atopic features. Clin Exp Allergy. 1998;28(7):834–838. doi:10.1046/j.1365-2222.1998.00313.x9720817
   PubMed Web of Science ®Google Scholar
• García-Robaina J, Vázquez-Moncholí C, Fierro J, Bonnet-Moreno C. Epidemiology of allergic reactions in beekeepers: a lower prevalence in subjects with more than 5 years exposure. Allergol Immunopathol. 1995;23(3):127–132.
   Google Scholar
• Annila IT, Karjalainen ES, Annila PA, Kuusisto PA. Bee and wasp sting reactions in current beekeepers. Ann Allergy Asthma Immunol. 1996;77(5):423–427. doi:10.1016/S1081-1206(10)63342-X8933782
   PubMed Web of Science ®Google Scholar
• Severino M, Bonadonna P, Passalacqua G. Large local reactions from stinging insects: from epidemiology to management. Curr Opin Allergy Clin Immunol. 2009;9(4):334–337. doi:10.1097/ACI.0b013e32832d066819458526
   PubMed Web of Science ®Google Scholar
• Graft DF, Schuberth KC, Kagey-Sobotka A, et al. A prospective study of the natural history of large local reactions after Hymenoptera stings in children. J Pediatr. 1984;104(5):664–668. doi:10.1016/S0022-3476(84)80940-36716215
   PubMed Web of Science ®Google Scholar
• Müller UR. Insect sting allergy: clinical picture, diagnosis and treatment. Insect Sting Allergy. 1990.
   Google Scholar
• Bilo BM, Bonifazi F. Epidemiology of insect-venom anaphylaxis. Curr Opin Allergy Clin Immunol. 2008;8(4):330–337. doi:10.1097/ACI.0b013e32830638c518596590
   PubMed Web of Science ®Google Scholar
• Bilo B, Rueff F, Mosbech H, Bonifazi F, Oude‐Elberink J, Hypersensitivity EIGoIV. Diagnosis of Hymenoptera venom allergy. Allergy. 2005;60(11):1339–1349. doi:10.1111/j.1398-9995.2005.00963.x16197464
   PubMed Web of Science ®Google Scholar
• Jennings A, Duggan E, Perry IJ, Hourihane JOB. Epidemiology of allergic reactions to hymenoptera stings in Irish school children. Pediatr Allergy Immunol. 2010;21(8):1166–1170. doi:10.1111/pai.2010.21.issue-820408970
   PubMed Web of Science ®Google Scholar
• Vetter RS. Wasp or hippopotamus? J Allergy Clin Immunol. 2000;106(1):196. doi:10.1067/mai.2000.106547
   Web of Science ®Google Scholar
• Ring J. History of allergy in antiquity Chem Immunol Allergy 2014;100:2–14.
   Google Scholar
• Oppenheimer J, Golden DB. Hymenoptera venom immunotherapy: past, present, and future. Ann Allergy Asthma Immunol. 2018;121(3):276–277. doi:10.1016/j.anai.2018.06.00629909053
   PubMed Web of Science ®Google Scholar
• Lichtenstein LM, Valentine MD, Sobotka AK. A case for venom treatment in anaphylactic sensitivity to Hymenoptera sting. N Engl J Med. 1974;290(22):1223–1227. doi:10.1056/NEJM1974053029022044133096
   PubMed Web of Science ®Google Scholar
• Galli SJ. Mary Hewitt Loveless, MD: the origin of venom immunotherapy. Ann Allergy Asthma Immunol. 2018;121(3):268–271. doi:10.1016/j.anai.2018.06.02029964225
   PubMed Web of Science ®Google Scholar
• Loveless MH, Nall TM. Use of polistes venom in petrolatum: arlacel repositories to immunize against yellow jacket wasp-sting allergy. J Immunol. 1965;94(5):785–793.14296300
   PubMed Web of Science ®Google Scholar
• Poulsen LK, Hummelshoj L. Triggers of IgE class switching and allergy development. Ann Med. 2007;39(6):440–456. doi:10.1080/0785389070144935417852040
   PubMed Web of Science ®Google Scholar
• Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693–704. doi:10.1038/nm.275522561833
   PubMed Web of Science ®Google Scholar
• Bradding P, Walls AF, Holgate ST. The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol. 2006;117(6):1277–1284. doi:10.1016/j.jaci.2006.02.03916750987
   PubMed Web of Science ®Google Scholar
• Simons FE. Anaphylaxis. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S161–181. doi:10.1016/j.jaci.2009.12.98120176258
   PubMed Web of Science ®Google Scholar
• Kalesnikoff J, Galli SJ. New developments in mast cell biology. Nat Immunol. 2008;9(11):1215–1223. doi:10.1038/ni.f.21618936782
   PubMed Web of Science ®Google Scholar
• Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2007;119(4):780–791. doi:10.1016/j.jaci.2007.01.02217321578
   PubMed Web of Science ®Google Scholar
• Eberlein-Konig B, Ullmann S, Thomas P, Przybilla B. Tryptase and histamine release due to a sting challenge in bee venom allergic patients treated successfully or unsuccessfully with hyposensitization. Clin Exp Allergy. 1995;25(8):704–712. doi:10.1111/cea.1995.25.issue-87584681
   PubMed Web of Science ®Google Scholar
• Jutel M, Muller UR, Fricker M, Rihs S, Pichler WJ, Dahinden C. Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils. Clin Exp Allergy. 1996;26(10):1112–1118. doi:10.1111/j.1365-2222.1996.tb00496.x8911695
   PubMed Web of Science ®Google Scholar
• Celesnik Smodis N, Silar M, Erzen R, Rijavec M, Kosnik M, Korosec P. Down-regulation of FcepsilonRI-mediated CD63 basophil response during short-term VIT determined venom-nonspecific desensitization. PLoS One. 2014;9(4):e94762. doi:10.1371/journal.pone.009476224733549
   PubMed Web of Science ®Google Scholar
• Meiler F, Zumkehr J, Klunker S, Ruckert B, Akdis CA, Akdis M. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med. 2008;205(12):2887–2898. doi:10.1084/jem.2008019319001136
   PubMed Web of Science ®Google Scholar
• Celesnik N, Vesel T, Rijavec M, et al. Short-term venom immunotherapy induces desensitization of FcepsilonRI-mediated basophil response. Allergy. 2012;67(12):1594–1600. doi:10.1111/all.1204423066930
   PubMed Web of Science ®Google Scholar
• Braga M, Quecchia C, Cavallucci E, et al. T regulatory cells in allergy. Int J Immunopathol Pharmacol. 2011;24(1 Suppl):55S–64S.21329567
   PubMed Web of Science ®Google Scholar
• Calzada D, Baos S, Cremades-Jimeno L, Cardaba B. Immunological mechanisms in allergic diseases and allergen tolerance: the role of treg cells. J Immunol Res. 2018;2018:6012053. doi:10.1155/2018/601205330013991
   PubMed Web of Science ®Google Scholar
• Malisan F, Briere F, Bridon JM, et al. Interleukin-10 induces immunoglobulin G isotype switch recombination in human CD40-activated naive B lymphocytes. J Exp Med. 1996;183(3):937–947. doi:10.1084/jem.183.3.9378642297
   PubMed Web of Science ®Google Scholar
• Defrance T, Vanbervliet B, Briere F, Durand I, Rousset F, Banchereau J. Interleukin 10 and transforming growth factor beta cooperate to induce anti-CD40-activated naive human B cells to secrete immunoglobulin A. J Exp Med. 1992;175(3):671–682. doi:10.1084/jem.175.3.6711371300
   PubMed Web of Science ®Google Scholar
• Burton OT, Logsdon SL, Zhou JS, et al. Oral immunotherapy induces IgG antibodies that act through FcgammaRIIb to suppress IgE-mediated hypersensitivity. J Allergy Clin Immunol. 2014;134(6):1310–1317 e1316. doi:10.1016/j.jaci.2014.05.04225042981
   PubMed Web of Science ®Google Scholar
• Kennedy Norton S, Barnstein B, Brenzovich J, et al. IL-10 suppresses mast cell IgE receptor expression and signaling in vitro and in vivo. J Immunol. 2008;180(5):2848–2854. doi:10.4049/jimmunol.180.5.284818292506
   PubMed Web of Science ®Google Scholar
• Sturm GJ, Varga EM, Roberts G, et al. EAACI guidelines on allergen immunotherapy: hymenoptera venom allergy. Allergy. 2018;73(4):744–764. doi:10.1111/all.1326228748641
   PubMed Web of Science ®Google Scholar
• Dhami S, Zaman H, Varga EM, et al. Allergen immunotherapy for insect venom allergy: a systematic review and meta‐analysis. Allergy. 2017;72(3):342–365. doi:10.1111/all.1307728120424
   PubMed Web of Science ®Google Scholar
• Boyle RJ, Elremeli M, Hockenhull J, et al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev. 2012; 10. doi:10.1002/14651858.CD008838.pub2
   Web of Science ®Google Scholar
• Golden DB, Kagey-Sobotka A, Norman PS, Hamilton RG, Lichtenstein LM. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med. 2004;351(7):668–674. doi:10.1056/NEJMoa02295215306668
   PubMed Web of Science ®Google Scholar
• Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med. 1978;299(4):157–161. doi:10.1056/NEJM19780727299040178446
   PubMed Web of Science ®Google Scholar
• Oude JE, De JM, Van SDH, Guyatt GH, Dubois A. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol. 2002;110(1):174–182. doi:10.1067/mai.2002.12582712110838
   PubMed Web of Science ®Google Scholar
• Oude Elberink J, Van Der Heide S, Guyatt G, Dubois A. Immunotherapy improves health‐related quality of life of adult patients with dermal reactions following yellow jacket stings. Clin Exp Allergy. 2009;39(6):883–889. doi:10.1111/cea.2009.39.issue-619364334
   PubMed Web of Science ®Google Scholar
• Pucci S, D’Alò S, De Pasquale T, Illuminati I, Makri E, Incorvaia C. Risk of anaphylaxis in patients with large local reactions to hymenoptera stings: a retrospective and prospective study. Clin Mol Allergy. 2015;13(1):21. doi:10.1186/s12948-015-0030-z26557045
   PubMedGoogle Scholar
• Sturm GJ, Kranzelbinder B, Schuster C, et al. Sensitization to Hymenoptera venoms is common, but systemic sting reactions are rare. J Allergy Clin Immunol. 2014;133(6):1635–1643. e1631. doi:10.1016/j.jaci.2013.10.04624365141
   PubMed Web of Science ®Google Scholar
• Bilò MB, Martini M, Pravettoni V, et al. Large local reactions to Hymenoptera stings: outcome of re‐stings in real life. Allergy. 2019. doi:10.1111/all.13863
   Web of Science ®Google Scholar
• Bilò MB, Ollert M, Blank S. The role of component-resolved diagnosis in Hymenoptera venom allergy. Curr Opin Allergy Clin Immunol. 2019;19(6):614–622. doi:10.1097/ACI.000000000000057431343438
   PubMed Web of Science ®Google Scholar
• Spillner E, Blank S, Jakob T. Hymenoptera allergens: from venom to “venome”. Front Immunol. 2014;5:77. doi:10.3389/fimmu.2014.0007724616722
   PubMed Web of Science ®Google Scholar
• Cifuentes L, Vosseler S, Blank S, et al. Identification of Hymenoptera venom–allergic patients with negative specific IgE to venom extract by using recombinant allergens. J Allergy Clin Immunol. 2014;133(3):909–910. doi:10.1016/j.jaci.2013.09.04724290287
   PubMed Web of Science ®Google Scholar
• Birnbaum J, Charpin D, Vervloet D. Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols. Clin Exp Allergy. 1993;23(3):226–230. doi:10.1111/cea.1993.23.issue-38472191
   PubMed Web of Science ®Google Scholar
• Laurent J, Smiejan J, Bloch‐Morot E, Herman D. Safety of Hymenoptera venom rush immunotherapy. Allergy. 1997;52(1):94–96. doi:10.1111/j.1398-9995.1997.tb02551.x9062635
   PubMed Web of Science ®Google Scholar
• Sturm G, Kränke B, Rudolph C, Aberer W. Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients. J Allergy Clin Immunol. 2002;110(6):928–933. doi:10.1067/mai.2002.12912412464961
   PubMed Web of Science ®Google Scholar
• Van der Zwan J, Flinterman J, Jankowski I, Kerckhaert J. Hyposensitisation to wasp venom in six hours. Br Med J (Clin Res Ed). 1983;287(6402):1329–1331. doi:10.1136/bmj.287.6402.1329
   Web of Science ®Google Scholar
• Roll A, Hofbauer G, Ballmer-Weber B, Schmid-Grendelmeier P. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy. J Invest Allerg Clin Immunol. 2006;16(2):79.
   PubMed Web of Science ®Google Scholar
• Malling HJ, Djurup R, Søndergaard I, Weeke B. Clustered immunotherapy with yellow jacket venom: evaluation of the influence of time interval on in vivo and in vitro parameters. Allergy. 1985;40(5):373–383. doi:10.1111/j.1398-9995.1985.tb00250.x4037258
   PubMed Web of Science ®Google Scholar
• Schuch A, Brockow K. Mastocytosis and anaphylaxis. Immunol Allergy Clin. 2017;37(1):153–164. doi:10.1016/j.iac.2016.08.017
   Web of Science ®Google Scholar
• González-de-Olano D, Matito A, Orfao A, Escribano L. Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes. F1000Research. 2016;5. doi:10.12688/f1000research.9565.1
   Google Scholar
• Gruzelle V, Ramassamy M, Bulai Lidiveanu C, Didier A, Mailhol C, Guilleminault L. Safety of ultra‐rush protocols for hymenoptera venom immunotherapy in systemic mastocytosis. Allergy. 2018;73(11):2260–2263. doi:10.1111/all.2018.73.issue-1129984458
   PubMed Web of Science ®Google Scholar
• Müller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol. 1992;89(2):529–535. doi:10.1016/0091-6749(92)90319-W1740583
   PubMed Web of Science ®Google Scholar
• Rueff F, Vos B, Oude Elberink J, et al. Predictors of clinical effectiveness of Hymenoptera venom immunotherapy. Clin Exp Allergy. 2014;44(5):736–746. doi:10.1111/cea.2014.44.issue-524447114
   PubMed Web of Science ®Google Scholar
• Hoffman DR, Jacobson RS. Allergens in hymenoptera venom XII: how much protein is in a sting. Ann Allergy. 1984;52(4):276–278.6711914
   PubMedGoogle Scholar
• Blank S, Seismann H, Michel Y, et al. Api m 10, a genuine A. mellifera venom allergen, is clinically relevant but underrepresented in therapeutic extracts. Allergy. 2011;66(10):1322–1329. doi:10.1111/all.2011.66.issue-1021658068
   PubMed Web of Science ®Google Scholar
• Fischer J, Teufel M, Feidt A, Giel KE, Zipfel S, Biedermann T. Tolerated wasp sting challenge improves health-related quality of life in patients allergic to wasp venom. J Allergy Clin Immunol. 2013;132(2):489–490. doi:10.1016/j.jaci.2013.03.01023639308
   PubMed Web of Science ®Google Scholar
• TSICOPOULOS A, Tonnel A, Wallaert B, Ramon P, Joseph M, Capron A. Short‐term decrease of skin‐test sensitivity after rush desensitization in Hymenoptera venom hypersensitivity. Clin Exp Allergy. 1990;20(3):289–294. doi:10.1111/j.1365-2222.1990.tb02686.x2364309
   PubMed Web of Science ®Google Scholar
• Lerch E, Müller UR. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol. 1998;101(5):606–612. doi:10.1016/S0091-6749(98)70167-89600496
   PubMed Web of Science ®Google Scholar
• Keating M, Kagey-Sobotka A, Hamilton RG, Yunginger J. Clinical and immunologic follow-up of patients who stop venom immunotherapy. J Allergy Clin Immunol. 1991;88(3):339–348. doi:10.1016/0091-6749(91)90095-61890261
   PubMed Web of Science ®Google Scholar
• Goldberg A, Confino‐Cohen R. Bee venom immunotherapy – how early is it effective? Allergy. 2010;65(3):391–395. doi:10.1111/j.1398-9995.2009.02198.x19839973
   PubMed Web of Science ®Google Scholar
• Goldberg A, Yogev A, Confino-Cohen R. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective. Int Arch Allergy Immunol. 2011;156(1):90–98. doi:10.1159/00032225821447964
   PubMed Web of Science ®Google Scholar
• Bernkopf K, Rönsch H, Spornraft-Ragaller P, Neumeister V, Bauer A. Safety and tolerability during build-up phase of a rush venom immunotherapy. Ann Allergy Asthma Immunol. 2016;116(4):360–365. doi:10.1016/j.anai.2016.02.01427055991
   PubMed Web of Science ®Google Scholar
• Kalogeromitros D, Makris M, Koti I, et al. A simple 3-day “rush” venom immunotherapy protocol: documentation of safety. Allergol Immunopathol (Madr). 2010;38(2):69–73. doi:10.1016/j.aller.2009.08.00219853357
   PubMed Web of Science ®Google Scholar
• Schiavino D, Nucera E, Pollastrini E, et al. Specific ultrarush desensitization in Hymenoptera venom-allergic patients. Ann Allergy Asthma Immunol. 2004;92(4):409–413. doi:10.1016/S1081-1206(10)61775-915104191
   PubMed Web of Science ®Google Scholar
• Cosme J, Spínola-Santos A, Pereira-Santos M, Pereira-Barbosa M. Venom Immunotherapy: a 20-year experience with an ultra-rush protocol (210-min). Eur Ann Allergy Clin Immunol. 2019;51(3):122–128. doi:10.23822/EurAnnACI.1764-1489.8530702236
   PubMed Web of Science ®Google Scholar
• Birnbaum J, Ramadour M, Magnan A, Vervloet D. Hymenoptera ultra‐rush venom immunotherapy (210 min): a safety study and risk factors. Clin Exp Allergy. 2003;33(1):58–64. doi:10.1046/j.1365-2222.2003.01564.x12534550
   PubMed Web of Science ®Google Scholar
• Mosbech H, Müller U, Behalf Of The Study Group* O. Side‐effects of insect venom immunotherapy: results from an EAACI multicenter study. Allergy. 2000;55(11):1005–1010. doi:10.1034/j.1398-9995.2000.00587.x11097308
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Epstein T. Systemic reactions to subcutaneous allergen immunotherapy. Immunol Allergy Clin. 2011;31(2):241–249. doi:10.1016/j.iac.2011.02.007
   Web of Science ®Google Scholar
• Bernstein DI, Wanner M, Borish L, Liss GM. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol. 2004;113(6):1129–1136. doi:10.1016/j.jaci.2004.02.00615208595
   PubMed Web of Science ®Google Scholar
• Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA. Survey of fatalities from skin testing and immunotherapy 1985–1989. J Allergy Clin Immunol. 1993;92(1):6–15. doi:10.1016/0091-6749(93)90030-J8335856
   PubMed Web of Science ®Google Scholar
• Ruëff F, Przybilla B, Biló MB, et al. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase. J Allergy Clin Immunol. 2010;126(1):105–111. e105. doi:10.1016/j.jaci.2010.04.02520542320
   PubMed Web of Science ®Google Scholar
• Patella V, Florio G, Giuliano A, et al. Hymenoptera venom immunotherapy: tolerance and efficacy of an ultrarush protocol versus a rush and a slow conventional protocol. J Allergy (Cairo). 2012;2012. doi:10.1155/2012/192192
   Google Scholar
• Müller UR, Haeberli G. Use of β-blockers during immunotherapy for Hymenoptera venom allergy. J Allergy Clin Immunol. 2005;115(3):606–610. doi:10.1016/j.jaci.2004.11.01215753911
   PubMed Web of Science ®Google Scholar
• Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol. 2004;114(2):371–376. doi:10.1016/j.jaci.2004.04.02915316518
   PubMed Web of Science ®Google Scholar
• Pitsios C, Demoly P, Bilò M, et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper. Allergy. 2015;70(8):897–909. doi:10.1111/all.2015.70.issue-825913519
   PubMed Web of Science ®Google Scholar
• Stoevesandt J, Hosp C, Kerstan A, Trautmann A. Hymenoptera venom immunotherapy while maintaining cardiovascular medication: safe and effective. Ann Allergy Asthma Immunol. 2015;114(5):411–416. doi:10.1016/j.anai.2015.03.00125952636
   PubMed Web of Science ®Google Scholar
• Brockow K, Kiehn M, Riethmüllerb C, Vieluf D, Berger J, Ring J. Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol. 1997;100(4):458–463. doi:10.1016/S0091-6749(97)70135-09338537
   PubMed Web of Science ®Google Scholar
• Kontou‐Fili K. ALLERGY Net: high omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy. 2008;63(3):376–378. doi:10.1111/j.1398-9995.2007.01604.x18269681
   PubMed Web of Science ®Google Scholar
• Schulze J, Rose M, Zielen S. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy. 2007;62(8):963–964. doi:10.1111/all.2007.62.issue-817484729
   PubMed Web of Science ®Google Scholar
• Stretz E, Oppel E, Räwer HC, et al. Overcoming severe adverse reactions to venom immunotherapy using anti‐Ig E antibodies in combination with a high maintenance dose. Clin Exp Allergy. 2017;47(12):1631–1639. doi:10.1111/cea.1299728802075
   PubMed Web of Science ®Google Scholar